To investigate the expression of Integrin alpha V/beta 3 (αvβ3) and transmembrane protein 16A (Tmem16a) in basal cell carcinoma of the eyelid and its correlation with vascular endothelial growth factor (VEGF). Methods: In this experimental study, 72 cases of basal cell carcinoma of eyelid after operation were enrolled in Zhengzhou People's Hospital from May 2013 to May 2017 as the study group, another 40 cases of normal tissue around the cancer as the control group, using immunohistochemical method to determine the expression of Integrin αvβ3, Tmem16a, VEGF protein, and to explore the relationship between Integrin αvβ3, Tmem16a protein and VEGF. The data were analyzed by t test, chi-square test, Logistic regression and Pearson correlation. Results: The positive rates of Integrin αvβ3, Tmem16a and VEGF in the study group were significantly higher than those in the control group (χ2 =16.94, 24.38, 23.94, P<0.05). The positive rates of Integrin αvβ3, Tmem16a and VEGF were related to proliferating cell nuclear antigen (PCNA) and tumor diameter (P<0.05), but not to the sex and age of patients (P>0.05). The expression of Integrin αvβ3 and Tmem16a was positively correlated with the expression of VEGF in eyelid basal cell carcinoma (r=0.642, 0.516, P<0.001). Conclusions: Integrin αvβ3 and Tmem16a in basal cell carcinoma in the presence of high expression, and correlated with tumor diameter and PCNA proliferation index, which could promote the expression of VEGF, accelerate the occurrence and progression of basal cell carcinoma of eyelid.
Rossato LA, Carneiro RC, Macedo EM, et al. Diagnosis of aggressive subtypes of eyelid basal cell carcinoma by 2-mm punch biopsy: Prospective and comparative study. Rev Col Bras Cir, 2016, 43(4): 262-269. DOI: 10.1590/0100-69912016004008.
Sakamoto Y, Ogita H, Komura H, et al. Involvement of nectin in inactivation of integrin alpha (v) beta (3) after the establishment of cell-cell adhesion. J Biol Chem, 2008, 283(1): 496-505. DOI:10.1074/jbc.M704195200.
Saleh GM, Desai P, Collin JRO, et al. Incidence of eyelid basal cell carcinoma in England: 2000-2010. Br J Ophthalmol, 2017,101(2): 209-212. DOI: 10.1136/bjophthalmol-2015-308261.
[8]
Pfeiffer MJ, Pfeiffer N, Valor C. Descriptive study on basal cell eyelid carcinoma. Arch Soc Esp Oftalmol, 2015, 90(9): 426-431.DOI: 10.1016/j.oftal.2014.12.001.
[9]
Cox KF, Margo CE. Role of vismodegib in the management of advanced periocular basal cell carcinoma. Cancer Control Cancer Center, 2016, 23(2): 133-139. DOI: 10.1177/107327481602300207.
[10]
Celebi ARC, Kiratli H, Soylemezoglu F. Evaluation of the' Hedgehog' signaling pathways in squamous and basal cell carcinomas of the eyelids and conjunctiva. Oncol Lett, 2016,
12
(1): 467-472. DOI: 10.3892/ol.2016.4625.
[11]
Chin C, Bradu A, Lim R, et al. Master/slave optical coherence tomography imaging of eyelid basal cell carcinoma. Appl Opt,2016, 55(26): 7378-7386. DOI: 10.1364/AO.55.007378.
[12]
Yang WC, Chen CY, Chou HC, et al. Angiogenic Factors in cord blood of preterm infants predicts subsequently developing bronchopulmonary dysplasia. Pediatr Neonatol, 2015, 56(6):382-385. DOI: 10.1016/j.pedneo.2015.02.001.
?ahan B, Çiftçi F, Özkan F, et al. The importance of frozen section-controlled ecxision in recurrent basal cell carcinoma of the eyelids. Turk J Ophthalmol, 2016, 46(6): 277-281. DOI:10.4274/tjo.48640.